Oncobit AG specializes in advanced molecular diagnostics, focusing on the development of innovative technologies for cancer detection and monitoring. The company employs a proprietary platform that utilizes next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) in blood samples. This technology enables the identification of genetic mutations and alterations associated with various cancers, providing valuable insights for personalized treatment strategies. By leveraging high-throughput sequencing and bioinformatics, Oncobit AG aims to enhance early detection and improve patient outcomes through precise and timely information.

In addition to its NGS capabilities, Oncobit AG integrates advanced data analytics and machine learning algorithms to interpret complex genomic data. This approach allows for the identification of specific biomarkers that can inform treatment decisions and monitor disease progression. The company's commitment to research and development ensures that its technologies remain at the forefront of cancer diagnostics, ultimately contributing to the advancement of precision medicine and better management of cancer care.

Switzerland

Oncobit is a medtech UZH Spin-off, enabling personalized cancer care by matching patients to the best cancer treatment available. We are developing cancer-specific genomic fingerprinting and personalized monitoring tests and provide therapy decision support.

Oncobit AG

Company Details